Bird Flu Is Evolving — Are Our Vaccines Keeping Up?

Why Scientists Are Working on a Nasal Spray Bird Flu Vaccine (and Why It Matters)

Bird flu is still evolving, and so is our approach to fighting it. We had the pleasure of having Dr. Chad Costley on the podcast recently, where he walked us through a Phase I trial for an intranasal H5N1 vaccine (aka a nasal spray that builds immunity right where the virus lands first—in your nose!). Even better, it trains your immune system to recognize multiple strains, not just one, which could bring us closer to a universal flu vaccine that provides broader protection and avoids the painstaking strain-matching process (which is imperfect). Add in dose-sparing potential that could stretch stockpiles during an outbreak, and this is the kind of science that gets us excited.

So, where are we right now? According to Brown’s Pandemic Center, it’s been pretty quiet lately. Since the start of 2026, we’ve seen bird flu pop up in 16 commercial and backyard flocks and 33 wild birds across the US. No new cases in dairy cattle since mid-December, and no new human cases globally. That’s good news, but let’s not let down our defenses. The time to build better tools is when things are calm, not when we’re in crisis mode.

This article walks through the research and the promise it holds, perhaps even beyond bird flu. Let’s discuss…

---

For more than two years, scientists have been sounding the alarm about the rapid evolution and expanding footprint of H5N1 avian influenza (bird flu). What was once primarily a bird pathogen has now infected dozens of mammalian species, including cattle in the U.S., and caused sporadic but severe human infections. None of this means a pandemic is inevitable, but it does underscore a critical question:

Do the preventative tools we have now match the threats we face?

BlueWillow Biologics’ new Phase I clinical trial suggests that next-generation, intranasal influenza vaccines could be part of the solution.

Why Bird Flu’s Evolution Matters

Seasonal flu mutates constantly, but H5N1 evolves faster than we can update vaccines. More concerning, it has:

• High fatality rates in documented human cases

• Broad host range, allowing it to infect mammals that can serve as “mixing vessels” for viral evolution

• Multiple genetic clades, meaning the virus exists as many distinct versions or “strains” at once

• Growing opportunities for spillover as outbreaks spread through wildlife and livestock

Vaccines targeted to one version of the bird flu virus may not protect against another. Most rely on intramuscular injection and produce strong body-wide systemic immunity, but relatively little mucosal immunity—the immune response in the nose and airways where flu first takes hold.

That’s where intranasal vaccines come in.

What the New Study Shows

The Phase I trial, published in Nature Communications, tested an intranasal H5N1 vaccine candidate using BlueWillow Biologics’ shelf-stable oil-in-water emulsion adjuvant (W₈₀5EC) to stimulate mucosal, cellular, and systemic immunity. Adjuvants are added to vaccines to enhance the immune response.

The key findings:

1. Safety Profile Was Strong

Across 40 healthy adults receiving doses with varying amounts of antigen or harmless pieces of the H5N1 bird flu virus, with or without the adjuvant, the intranasal formulations were safe and well tolerated.

2. Only the Intranasal Vaccine Stimulated a Robust Immune Response

Participants who received the intranasal adjuvanted vaccine showed:

• Broad systemic priming, a later booster dose with an approved H5 flu vaccine given through a typical intramuscular injection revealed that the immune system was already trained to fight the virus

• Mucosal immunity, the immune response in the nose and airways where flu first takes hold, which could help block infection at the point of entry

• Cellular immune responses, important for clearing infected cells and for the long-term protection from a vaccine (“immune memory”)

• Systemic antibody responses, offering layered protection

This breadth of response has not been seen in prior mucosal H5 vaccine candidates.

3. Significant Cross-Clade Recognition

The adjuvanted vaccine primed the immune system to respond to multiple distinct H5N1 strains, not just one. This is essential because any emerging strain may look different from the one included in a vaccine vial.

4. Potential for Dose-Sparing

If confirmed, this could allow vaccine stockpiles to stretch further, which is critical during a fast-moving outbreak.

Why Intranasal Matters in the Bigger Picture

Even if H5N1 never becomes easily transmissible between humans, preparedness demands countermeasures that:

• Target multiple versions of the flu virus, not just a single strain

• Support rapid manufacturing and distribution

• Offer needle-free delivery, which overcomes patient hesitancy and simplifies mass vaccination

• Induce mucosal immunity, which may reduce both disease severity and infectiousness

This trial doesn’t prove the vaccine prevents infection or transmission—that requires larger trials. But the early signals matter because they point to what our future toolkit could look like: vaccines that activate immune defenses exactly where respiratory viruses enter the body.

The Risk Landscape Is Changing

H5N1 is now entrenched in the global ecosystem. That means:

• More opportunities for the virus to mix and mutate

• More interactions between infected animals and humans

• More chances for the virus to acquire traits that could make person-to-person spread easier

Traditional intramuscular vaccines—while lifesaving—may not be sufficient on their own in situations requiring rapid, broad, and easily deployable immunity.

A Glimpse of What “Preparedness 2.0” Could Be

BlueWillow’s NanoVax^® adjuvant is now one of the most advanced intranasal vaccine platforms in clinical development. If future trials succeed, similar formulations could be adapted for other high-risk respiratory viruses, including influenza A subtypes, RSV, and coronaviruses.

The COVID-19 pandemic taught us that waiting for a pathogen to show efficient human-to-human spread before investing in countermeasures is too late.

This intranasal H5N1 vaccine isn’t a final answer, but it represents a new direction, one aligned with what experts say we need:

• Broader immunity

• Faster scalability

• Mucosal defenses

• Vaccine affordability

As H5N1 continues to evolve, the question isn’t just whether the virus will change—it’s whether we will be ready.

Stay Curious,

Unbiased Science